Evidence map›Paper›PMID 35833145›Full record

ArticleFrontiers in immunology2022

Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation.

Elena Crespo, Anna Vidal-Alabró, Thomas Jouve, Pere Fontova, Maik Stein, Sonila Mocka, Maria Meneghini, Anett Sefrin, Petra Hruba, Montserrat Gomà and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 5 countries.

Elena CrespoNephrology and Transplant Laboratory, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
Anna Vidal-AlabróExperimental Nephrology and Transplantation Laboratory, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain.
Thomas JouveNephrology and Transplant Laboratory, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
Pere FontovaExperimental Nephrology and Transplantation Laboratory, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain.
Maik SteinBerlin Center for Advanced Therapies (BeCAT), Berlin, Germany.
Sonila MockaExperimental Nephrology and Transplantation Laboratory, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain.
Maria MeneghiniNephrology and Transplant Laboratory, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
Anett SefrinBerlin Center for Advanced Therapies (BeCAT), Berlin, Germany.
Petra HrubaDepartment of Nephrology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czechia.
Montserrat GomàPathology Department, Bellvitge University Hospital, Barcelona, Spain.
Alba TorijaNephrology and Transplant Laboratory, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
Laura DonadeuNephrology and Transplant Laboratory, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
Alex FavàKidney Transplant Unit, Nephrology Department, Bellvitge University Hospital, Barcelona, Spain.
Josep M CruzadoKidney Transplant Unit, Nephrology Department, Bellvitge University Hospital, Barcelona, Spain.
Edoardo MelilliKidney Transplant Unit, Nephrology Department, Bellvitge University Hospital, Barcelona, Spain.
Francesc MoresoKidney Transplant Unit and Nephrology Department, Vall d'Hebron Hospital, Barcelona, Spain.
Ondrej ViklickyDepartment of Nephrology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czechia.
Frederike BemelmanRenal Transplant Unit, Department of Internal Medicine, Amsterdam University Medical Centers, Academic Medical Center-University of Amsterdam, Amsterdam, Netherlands.
Petra ReinkeBerlin Center for Advanced Therapies (BeCAT), Berlin, Germany.
Josep GrinyóDepartment of Clinical Sciences, Barcelona University, Barcelona, Spain.
Nuria LloberasExperimental Nephrology and Transplantation Laboratory, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain.
Oriol BestardNephrology and Transplant Laboratory, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
Bellvitge University Hospital · ESInstitut d'Investigació Biomédica de Bellvitge · ESVall d'Hebron Institut de Recerca · ESVall d'Hebron Hospital Universitari · ESBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEInstitute of Clinical and Experimental Medicine · CZHumboldt-Universität zu Berlin · DEUniversitat de Barcelona · ESUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Achieving fast immunosuppression blood exposure after kidney transplantation is key to abrogating both preformed and

Indexed as

Cytochrome P-450 CYP3AKidney TransplantationMemory B CellsTacrolimusT-LymphocytesHumansPolymorphism, Single NucleotideRisk AssessmentCYP3A protein, humanCytochrome P-450 CYP3ATacrolimusacute rejectioncalcineurin inhibitors immunosuppressiongeneticsimmunobiologykidney transplantation

Identifiers

PMID35833145
PMCPMC9272702
OpenAlexW4283576715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.